• Alkermes flagged new clinical data on alixorexton and LUMRYZ for disclosure at Sleep Europe 2026 in Maastricht on Oct. 20-23.
• Previously published phase 2 Vibrance-1 results for alixorexton in narcolepsy type 1 will be presented, alongside longer-term extension findings.
• Management framed the extension data as supporting sustained symptom improvement with continued dosing, without citing specific efficacy measures.
• Detailed phase 3 REVITALYZ results for investigational LUMRYZ use in idiopathic hypersomnia will be presented in a late-breaking trial session on Oct. 23.
• LUMRYZ is not approved for idiopathic hypersomnia, with Alkermes barred from marketing it for that use before March 1, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013711970) on October 13, 2026, and is solely responsible for the information contained therein.